At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 8 enrolled
Drug / intervention
ACTH +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.
In Brief
A Phase 3 clinical trial evaluating ACTH and Placebo for Multiple Sclerosis, Relapsing-Remitting. Completed, enrolled 8 participants across 5 sites.
Detailed Summary
This is a study of Acthar gel (ACTH) in patients with relapsing multiple sclerosis who are experiencing chronic fatigue.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Relapsing-Remitting
CountriesUnited States
CollaboratorsMallinckrodt
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartMay 2015
Primary CompletionJun 2017
Study CompletionDec 2018
TodayJul 2026
First PostedDec 12, 2014
Enrollment StartMay 22, 2015
Primary CompletionJun 20, 2017
Study CompletionDec 13, 2018
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.6 years ago
Interventions
ACTHdrug
ACTH injections twice weekly for 28 weeks.
Placebodrug
Placebo injections twice weekly for 28 weeks.